291 related articles for article (PubMed ID: 26111953)
1. Xerosis and pruritus as major EGFRI-associated adverse events.
Clabbers JMK; Boers-Doets CB; Gelderblom H; Stijnen T; Lacouture ME; van der Hoeven KJM; Kaptein AA
Support Care Cancer; 2016 Feb; 24(2):513-521. PubMed ID: 26111953
[TBL] [Abstract][Full Text] [Related]
2. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
3. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
4. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
5. General management strategy for epidermal growth factor receptor inhibitor-associated papulopustular eruption.
Farahnik B; Kwong B; Murase J
J Am Acad Dermatol; 2016 Nov; 75(5):e191. PubMed ID: 27745649
[No Abstract] [Full Text] [Related]
6. EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Chiang TY; Hsu HC; Jane SW; Chen SC
Support Care Cancer; 2020 Oct; 28(10):4771-4779. PubMed ID: 31974771
[TBL] [Abstract][Full Text] [Related]
7. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
Amitay-Laish I; David M; Stemmer SM
Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
[TBL] [Abstract][Full Text] [Related]
8. Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch.
Boers-Doets CB; Gelderblom H; Lacouture ME; Bredle JM; Epstein JB; Schrama NA; Gall H; Ouwerkerk J; Brakenhoff JA; Nortier JW; Kaptein AA
Eur J Oncol Nurs; 2013 Dec; 17(6):802-7. PubMed ID: 23571183
[TBL] [Abstract][Full Text] [Related]
9. Skin Toxicities During Colorectal Cancer Chemotherapy: Incidence and Pearls of Treatment in Our Experience.
Panariello L; Donnarumma M; Iaffaioli RV; Chiodini P; Annunziata MC; Peduto T; Fabbrocini G
Clin Colorectal Cancer; 2020 Dec; 19(4):e235-e242. PubMed ID: 32665093
[TBL] [Abstract][Full Text] [Related]
10. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
Lacouture ME; Anadkat MJ; Bensadoun RJ; Bryce J; Chan A; Epstein JB; Eaby-Sandy B; Murphy BA;
Support Care Cancer; 2011 Aug; 19(8):1079-95. PubMed ID: 21630130
[TBL] [Abstract][Full Text] [Related]
11. A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors.
Wong SF; Lindgren A; Mummaneni M; Byun T; Vasko C; Arenos R; Alexson E; Osann K
J Support Oncol; 2010; 8(5):202-8. PubMed ID: 21086877
[TBL] [Abstract][Full Text] [Related]
12. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Wagner LI; Berg SR; Gandhi M; Hlubocky FJ; Webster K; Aneja M; Cella D; Lacouture ME
Support Care Cancer; 2013 Apr; 21(4):1033-41. PubMed ID: 23128934
[TBL] [Abstract][Full Text] [Related]
13. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
14. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
[TBL] [Abstract][Full Text] [Related]
15. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
Wnorowski AM; de Souza A; Chachoua A; Cohen DE
Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
[TBL] [Abstract][Full Text] [Related]
16. Effects of Colloidal Oatmeal Lotion on Symptoms of Dermatologic Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors.
Ke YT; Kuo CC
Adv Skin Wound Care; 2017 Jan; 30(1):27-34. PubMed ID: 27984271
[TBL] [Abstract][Full Text] [Related]
17. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.
Yuan C; Wang B
J Cosmet Dermatol; 2023 Aug; 22(8):2150-2157. PubMed ID: 36924348
[TBL] [Abstract][Full Text] [Related]
18. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
Lacouture ME; Maitland ML; Segaert S; Setser A; Baran R; Fox LP; Epstein JB; Barasch A; Einhorn L; Wagner L; West DP; Rapoport BL; Kris MG; Basch E; Eaby B; Kurtin S; Olsen EA; Chen A; Dancey JE; Trotti A
Support Care Cancer; 2010 Apr; 18(4):509-22. PubMed ID: 20145956
[TBL] [Abstract][Full Text] [Related]
19. [Adverse cutaneous effects and quality of life in patients treated with mTOR inhibitors for renal carcinoma].
Voilliot-Trotot C; Granel-Brocard F; Geoffrois L; Tréchot P; Nguyen-Thi P; Schmutz JL; Barbaud A
Ann Dermatol Venereol; 2013 May; 140(5):353-62. PubMed ID: 23663707
[TBL] [Abstract][Full Text] [Related]
20. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
Fabbrocini G; Panariello L; Cacciapuoti S; Bianca D; Ayala F
Dermatitis; 2012; 23(5):237-8. PubMed ID: 23010833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
